New diabetes pill QLG1091 goes Head-to-Head with rybelsus in major trial
NCT ID NCT07487103
First seen Apr 21, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This study compares a new drug, QLG1091, to an approved drug, Rybelsus, in adults with type 2 diabetes who are already taking metformin. About 478 participants will take either QLG1091 or Rybelsus for 26 weeks to see if the new drug works as well at lowering blood sugar. The goal is to manage diabetes, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.